ABOUT NEWS & EVENTS INVESTORS CAREERS COUNTRIES CONTACT US VOLUNTEER CLIENT LOGIN Journey Solutions Experience SOLUTIONS OFFERED BY Clinical Research Incorporates Dedicated Therapeutic Expertise Patient Populations Strategic Locations Phase 1, First in Human Phase IIa, Proof of Concept Early Product Development Ethnobridging Clinical PK/PD and Pharmacometrics Services Bioanalytical and Biomarkers Bioequivalence Studies Volunteer to Participate Clinical Research Solutions Early Phase Services Phase II-III Services Peri/Post-Approval Services Clinical Logistics Services Solutions Early Phase Services More of What You Need for a Stronger Start in Phase I Your journey from new molecule to new medicine starts with appropriate subjects, world class facilities, and more timely results. PAREXEL provides comprehensive early phase testing services through our own hospital-based clinical units on three continents. This ensures the highest patient safety standards, on-site lab facilities, and quick, in-house access to all of the healthy volunteers and diverse patient populations you need through our global patient database. We can even perform your Phase I trials across multiple locations at once, thanks to our harmonized Standardized Operating Procedures and integrated, Software-as-a-Service (SaaS)-based technologies that expedite vital decision-making in real time, wherever you need us to be, worldwide. All to get you faster results and more accurate, useful data from First in Human through Proof of Concept, so your team has the information it needs sooner to continue with the next part of your journey. Share Print First in Human Learn about our first-in-man - or first-in-human (FiH) - and other Phase I safety studies. learn more Key Offerings Phase 1, First in Human With participants safety paramount, PAREXEL® Early Phase has developed a superior range of services for the conduct of first-in-man - or first-in-human (FiH) - and other Phase I safety studies, giving you the assurance that your compound will move into... read more Clinical PK/PD and Pharmacometrics Services The attrition rate in the pharmaceutical industry remains high, with a Phase III failure rate of 40-50%. To address this issue, there is now a larger emphasis on quantitative predictions and translational science from the early exploratory stage... read more Ethnobridging PAREXEL® Early Phase are world leaders in the performance of ethnobridging clinical trials. As inclusion of Asian countries in global drug development strategies and registration of drugs in the Asia Pacific region has become increasingly important in recent years... read more Bioanalytical and Biomarkers Bioanalysis is the discipline that allows quantitative determination of chemical entities and biomarkers in biological matrices. PAREXEL® Early Phase offers the highest quality bioanalytical services for qualitative and quantitative drug, metabolite, and biomarker analysis in a variety of matrices. read more Key Materials eBROCHURE Starting Stronger in Phase I Through IIA Adding value from first-in-human through proof-of-concept.Achieve success through early testing of compounds in patients and healthy volunteers. Read more. POSTER Phase 1B Study to Investigate PL37 Download the poster from PAREXEL® on a Phase 1b Study to Investigate Pl37, the first dual Enkephalinase Inhibitor (Denki), in two Experimental Human Pain Models. Click here. CAREERS AT PAREXEL® If you are inspired to make a difference in the world, we can help you make it possible. Search positions worldwide PAREXEL International Corp. +1 781 487 9900 195 West Street Waltham, MA 02451 ABOUT PAREXEL® NEWS & EVENTS INVESTORS VOLUNTEER CONTACT CLIENT LOGIN LIQUENT® HERON™ Commercialization CLINICAL TRIAL INVESTIGATOR SITE MAP TERMS OF SERVICE PRIVACY POLICY © 2014 All Rights Reserved. PAREXEL, PAREXEL PACE, Perceptive Informatics, Perceptive, Perceptive MyTrials, ClinPhone, DataLabs, TrialWorks, IMPACT, Liquent, Liquent Insight and Technology Aligned, Your Journey. Our Mission are registered trademarks or trademarks of PAREXEL International Corporation or its subsidiaries.